肠型胃腺癌组织CDX2表达与临床表现和病理特征的关系

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (2007 KB)
输出: BibTeX | EndNote (RIS)

摘要目的分析肠型胃腺癌患者胃癌组织中尾侧型同源转录因子2(CDX2)免疫组织化学情况与临床表现和病理特征的关系。方法回顾性收集2022年1-12月联勤保障部队第909医院手术切除的肠型胃腺癌90例患者临床资料。根据CDX2免疫组织化学染色情况将所有患者分为CDX2阳性组和CDX2阴性组。比较两组患者间的临床表现和病理学资料特点、免疫和靶向治疗分子特征,分析CDX2表达与患者二代基因测序结果关系。结果根据胃癌组织中CDX2和细胞角蛋白7(CK7)免疫组化染色结果划分,CDX2阳性/CK7阳性共38例(42.22%),是最常见表达模式,其次为CDX2阴性/CK7阳性共30例(33.33%),CDX2阳性/CK7阴性16例(17.78%),CDX2阴性/CK7阴性6例(6.67%)。CDX2阳性组患者的肿瘤最大直径[(2.56±0.85)cm]小于CDX2阴性组[(3.41±0.93)cm],差异有统计学意义(P<0.001)。与CDX2阴性组相比,CDX2阳性者的组织学分级G2~G4患者比例(66.67% vs. 88.89%)低,肿瘤分期T3~T4比例(25.93% vs. 66.67%)低,淋巴管血管侵犯(18.52% vs. 55.56%)、神经周围侵犯(14.81% vs. 50.00%)及淋巴结转移比例(14.81% vs. 61.11%)均低(P<0.05)。CDX2阴性患者的HER-2表达阳性比例(6.67% vs. 50.00%)更低(P<0.05)。CDX2阳性患者基因改变多与受体酪氨酸激酶(TRK)基因相关,包括EGFR、ERBB2、ERBB3、DDR2和MET,而CDX2阴性患者似乎与肿瘤抑制基因的改变更密切相关,包括BRCA2、PETN、RB1、SMARCA4、TSC1和ATRX。结论肠型胃腺癌具有一定异质性,可根据CDX2的表达情况分为两种亚型。CDX2阳性和CDX2阴性患者间具有不同的病理和分子特征,并可能具有不同的预后,值得进一步研究。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	汤丽军
	耿月华
	许家伦
	黄江宾
	杨立民

关键词 ：胃癌, 分子特征, 病理学, 尾侧型同源转录因子2

Abstract：Objective To analyze the relationship between immunohistochemical patterns of caudal type homeobex transcription factor 2 (CDX2) in gastric cancer tissue of patients with intestinal adenocarcinoma and its clinical and pathological features. Methods Clinical data of 90 patients with intestinal gastric adenocarcinoma who underwent surgical resection in the 909th Hospital of PLA Joint Logistics Support Force from January 2022 to December 2022 were retrospectively collected. According to the immunohistochemical staining of CDX2, all patients were divided into CDX2 positive and CDX2 negative groups. The clinical manifestations, pathological data, molecular characteristics of immunological and targeted therapy, and the relationship between CDX2 expression and second-generation gene sequencing results were compared between the two groups. Results According to immunohistochemical staining of CDX2 and CK7 in gastric cancer tissue, CDX2 positive/CK7 positive in 38 cases (42.22%) was the most common expression pattern, followed by CDX2 negative/CK7 positive in 30 cases (33.33%), CDX2 positive/CK7 negative in 16 cases (17.78%), and CDX2 negative/CK7 negative in 6 cases (6.67%). The maximum diameter of the tumor in the CDX2 positive group (2.56±0.85) cm was smaller than that in the CDX2 negative group [(3.41±0.93) cm] (P<0.001). Compared with the CDX2 negative group, the proportion of patients with DX2 positive histological grade G2-G4 was lower (25.93% vs. 66.67%), the tumor stage T3-T4 was lower (25.93% vs. 66.67%), the proportion of lymphatic vessel vascular invasion (25.93% vs. 66.67%), perineural invasion (14.81% vs. 50.00%) and lymph node metastasis was lower (14.81% vs. 61.11%) (P<0.05). The positive proportion of HER-2 expression (6.67%) was lower in CDX2 negative patients (50.00%) (P<0.05). The gene changes in CDX2 positive patients are mostly related to tyrosine kinase receptor (TRK) genes, including EGFR, ERBB2, ERBB3, DDR2 and MET, while those in CDX2 negative patients seem to be more closely related to changes in Tumor suppressor gene, including BRCA2, PETN, RB1, SMARCA4, TSC1 and ATRX. Conclusions Intestinal gastric adenocarcinoma has certain heterogeneity and can be divided into two subtypes according to CDX2 expression. CDX2-positive and CDX2 -negative patients have different pathological and molecular characteristics and may have different prognosis, which is worthy of further study.

Key words： gastric cancer molecular characteristics pathology CDX2

收稿日期: 2023-10-20

R737.3

基金资助:福建省医学创新课题(2018-CX-38);第九〇九医院科研项目(20YQ005)

通讯作者: 杨立民,E-mail: ylm013@163.com

作者简介: 汤丽军,本科学历,住院医师。

引用本文:

汤丽军, 耿月华, 许家伦, 黄江宾, 杨立民. 肠型胃腺癌组织CDX2表达与临床表现和病理特征的关系[J]. 武警医学, 2024, 35(5): 384-388. TANG Lijun, GENG Yuehua, XU Jialun, HUANG Jiangbin, YANG Limin. Relationship between CDX2 expression in intestinal gastric adenocarcinoma tissue and clinical and pathological characteristics. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(5): 384-388.

链接本文:

https://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 https://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2024/V35/I5/384

[1]	中华医学会肿瘤学分会. 中华医学会胃癌临床诊疗指南(2021版)[J]. 中华医学杂志, 2022, 102(16):1169-1189.
[1]	中华医学会肿瘤学分会. 中华医学会胃癌临床诊疗指南(2021版)[J]. 中华医学杂志, 2022, 102(16):1169-1189.
[2]	Sexton R E, Al Hallak M N, Diab M, et al. Gastric cancer: a comprehensive review of current and future treatment strategies [J]. Cancer Metastasis Rev, 2020, 39(4): 1179-1203.
[2]	Sexton R E, Al Hallak M N, Diab M, et al. Gastric cancer: a comprehensive review of current and future treatment strategies [J]. Cancer Metastasis Rev, 2020, 39(4): 1179-1203.
[3]	李建芳, 余俊贤, 严超, 等. 胃癌基础与转化研究的热点问题[J]. 外科理论与实践, 2023, 28(1):7-16.
[3]	李建芳, 余俊贤, 严超, 等. 胃癌基础与转化研究的热点问题[J]. 外科理论与实践, 2023, 28(1):7-16.
[4]	Wang Q, Liu G, Hu C. Molecular classification of gastric adenocarcinoma[J]. Gastroenterol Res, 2019, 12(6): 275-282.
[4]	Wang Q, Liu G, Hu C. Molecular classification of gastric adenocarcinoma[J]. Gastroenterol Res, 2019, 12(6): 275-282.
[5]	马刚, 张汝鹏, 梁寒. 幽门螺杆菌与胃癌相关的研究进展[J]. 中国肿瘤临床, 2023, 50(1):44-48.
[5]	马刚, 张汝鹏, 梁寒. 幽门螺杆菌与胃癌相关的研究进展[J]. 中国肿瘤临床, 2023, 50(1):44-48.
[6]	Speck O, Tang W, Morgan D R, et al. Three molecular subtypes of gastric adenocarcinoma have distinct histochemical features reflecting Epstein-Barr virus infection status and neuroendocrine differentiation [J]. Appl Immunohistochem Mol Morphol, 2015, 23(9): 633-645.
[6]	Speck O, Tang W, Morgan D R, et al. Three molecular subtypes of gastric adenocarcinoma have distinct histochemical features reflecting Epstein-Barr virus infection status and neuroendocrine differentiation [J]. Appl Immunohistochem Mol Morphol, 2015, 23(9): 633-645.
[7]	Chen T, Yang C, Xi Z, et al. Reduced caudal type homeobox 2 (CDX2) promoter methylation is associated with curcumin’s suppressive effects on epithelial-mesenchymal transition in colorectal cancer cells[J]. Med Sci Monit, 2020, 26: e926443.
[7]	Chen T, Yang C, Xi Z, et al. Reduced caudal type homeobox 2 (CDX2) promoter methylation is associated with curcumin’s suppressive effects on epithelial-mesenchymal transition in colorectal cancer cells[J]. Med Sci Monit, 2020, 26: e926443.
[8]	王晓通, 孔凡彪, 李雷, 等. SIVA-1基因和Cdx2基因在胃癌发生发展中的作用、作用机制及其相互作用研究进展[J]. 山东医药, 2023, 63(9):111-114.
[8]	王晓通, 孔凡彪, 李雷, 等. SIVA-1基因和Cdx2基因在胃癌发生发展中的作用、作用机制及其相互作用研究进展[J]. 山东医药, 2023, 63(9):111-114.
[9]	Chai D, Du H, Li K, et al. CDX2 and Reg IV expression and correlation in gastric cancer[J]. BMC Gastroenterol, 2021, 21(1):92.
[9]	Chai D, Du H, Li K, et al. CDX2 and Reg IV expression and correlation in gastric cancer[J]. BMC Gastroenterol, 2021, 21(1):92.
[10]	司海, 刘然, 熊中原, 等. 细胞角蛋白的表达水平与结直肠癌临床病理学特征的相关性研究[J]. 首都医科大学学报, 2022, 43(1):127-131.
[10]	司海, 刘然, 熊中原, 等. 细胞角蛋白的表达水平与结直肠癌临床病理学特征的相关性研究[J]. 首都医科大学学报, 2022, 43(1):127-131.
[11]	Park D Y, Srivastava A, Kim G H, et al. CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance [J]. Mod Pathol, 2010, 23(1): 54-61.
[11]	Park D Y, Srivastava A, Kim G H, et al. CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance [J]. Mod Pathol, 2010, 23(1): 54-61.
[12]	Tsai J H, Jeng Y M, Chen K H, et al. An integrative morphomolecular classification system of gastric carcinoma with distinct clinical outcomes[J]. Am J Surg Pathol, 2020, 44(8): 1017-1030.
[12]	Tsai J H, Jeng Y M, Chen K H, et al. An integrative morphomolecular classification system of gastric carcinoma with distinct clinical outcomes[J]. Am J Surg Pathol, 2020, 44(8): 1017-1030.
[13]	张赟, 陈祎, 马亮, 等. 尾侧同源盒转录因子2在胃粘膜肠上皮化生及肠型胃癌中的表达研究[J]. 贵州医药, 2022, 46(5):785-786.
[13]	张赟, 陈祎, 马亮, 等. 尾侧同源盒转录因子2在胃粘膜肠上皮化生及肠型胃癌中的表达研究[J]. 贵州医药, 2022, 46(5):785-786.
[14]	冯永恒, 郑泽群, 刘霜月, 等. Vater壶腹部腺癌的病理分型及临床特征分析[J]. 临床肝胆病杂志, 2020, 36(5):1104-1108.
[14]	冯永恒, 郑泽群, 刘霜月, 等. Vater壶腹部腺癌的病理分型及临床特征分析[J]. 临床肝胆病杂志, 2020, 36(5):1104-1108.
[15]	Moskaluk C A, Zhang H, Powell S M, et al. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays[J]. Mod Pathol, 2003, 16(9):913-919.
[15]	Moskaluk C A, Zhang H, Powell S M, et al. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays[J]. Mod Pathol, 2003, 16(9):913-919.
[16]	Chai D, Du H, Li K, et al. CDX2 and Reg IV expression and correlation in gastric cancer[J]. BMC Gastroenterol, 2021, 21(1): 92.
[16]	Chai D, Du H, Li K, et al. CDX2 and Reg IV expression and correlation in gastric cancer[J]. BMC Gastroenterol, 2021, 21(1): 92.
[17]	田春方, 井海燕, 王潍博, 等. 374例根治术后肠型胃癌患者预后的影响因素分析[J]. 中国肿瘤临床, 2021, 48(11):559-565.
[17]	田春方, 井海燕, 王潍博, 等. 374例根治术后肠型胃癌患者预后的影响因素分析[J]. 中国肿瘤临床, 2021, 48(11):559-565.
[18]	辛磊, 宋波, 王莉, 等. 淋巴结转移率和病理学淋巴结分期对胃癌根治术后患者的预后评估[J]. 中华内分泌外科杂志, 2021, 15(3): 293-298.
[18]	辛磊, 宋波, 王莉, 等. 淋巴结转移率和病理学淋巴结分期对胃癌根治术后患者的预后评估[J]. 中华内分泌外科杂志, 2021, 15(3): 293-298.
[19]	Choi S, Park S, Kim H, et al. Gastric cancer: Mechanisms, biomarkers, and therapeutic approaches[J]. Biomedicines, 2022, 10(3): 543.
[19]	Choi S, Park S, Kim H, et al. Gastric cancer: Mechanisms, biomarkers, and therapeutic approaches[J]. Biomedicines, 2022, 10(3): 543.
[20]	Jin X, Liu Z, Yang D, et al. Recent progress and future perspectives of immunotherapy in advanced gastric cancer [J]. Front Immunol, 2022, 13: 948647.
[20]	Jin X, Liu Z, Yang D, et al. Recent progress and future perspectives of immunotherapy in advanced gastric cancer [J]. Front Immunol, 2022, 13: 948647.
[21]	童刚领, 程勃然, 吴烜, 等. 曲妥珠单抗联合FLOT方案围手术期治疗可手术HER-2阳性进展期胃癌的疗效和安全性[J]. 现代肿瘤医学, 2021, 29(4): 616-620.
[21]	童刚领, 程勃然, 吴烜, 等. 曲妥珠单抗联合FLOT方案围手术期治疗可手术HER-2阳性进展期胃癌的疗效和安全性[J]. 现代肿瘤医学, 2021, 29(4): 616-620.
[22]	吴小芳, 尹方, 吴英芬, 等. 幽门螺杆菌感染胃癌发生风险与TP53基因多态性分析[J]. 中华医院感染学杂志, 2021, 31(9): 1301-1304.
[22]	吴小芳, 尹方, 吴英芬, 等. 幽门螺杆菌感染胃癌发生风险与TP53基因多态性分析[J]. 中华医院感染学杂志, 2021, 31(9): 1301-1304.
[23]	Nemtsova M V, Kalinkin A I, Kuznetsova E B, et al. Clinical relevance of somatic mutations in main driver genes detected in gastric cancer patients by next-generation DNA sequencing[J]. Sci Rep, 2020, 10(1): 504.
[23]	Nemtsova M V, Kalinkin A I, Kuznetsova E B, et al. Clinical relevance of somatic mutations in main driver genes detected in gastric cancer patients by next-generation DNA sequencing[J]. Sci Rep, 2020, 10(1): 504.